Human Triosephosphate isomerase(TPI1) ELISA kit

Code CSB-EL024102HU
Size 96T,5×96T,10×96T
Price Request a Quote or Start an on-line Chat
Trial Size 24T ELISA Kit Trial Size (Only USD$150/ kit)
* The sample kit cost can be deducted from your subsequent orders of 96T full size kits of the same analyte at 1/5 per kit, until depleted in 6 months. Apply now

Product Details

Target Name
triosephosphate isomerase 1
Alternative Names
TPI1 ELISA Kit; TPI ELISA Kit; Triosephosphate isomerase ELISA Kit; TIM ELISA Kit; EC 5.3.1.1 ELISA Kit; Methylglyoxal synthase ELISA Kit; EC 4.2.3.3 ELISA Kit; Triose-phosphate isomerase ELISA Kit
Abbreviation
TPI1
Uniprot No.
Species
Homo sapiens (Human)
Sample Types
serum, plasma, tissue homogenates, cell lysates
Detection Range
28 pg/mL-1800 pg/mL
Sensitivity
7 pg/mL
Assay Time
1-5h
Sample Volume
50-100ul
Detection Wavelength
450 nm
Research Area
Metabolism
Assay Principle
quantitative
Measurement
Sandwich
Precision
Intra-assay Precision (Precision within an assay): CV%<8%        
Three samples of known concentration were tested twenty times on one plate to assess.    
Inter-assay Precision (Precision between assays): CV%<10%        
Three samples of known concentration were tested in twenty assays to assess.      
               
Linearity
To assess the linearity of the assay, samples were spiked with high concentrations of human TPI1 in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.  
  Sample Serum(n=4)    
1:1 Average % 106    
Range % 100-112    
1:2 Average % 95    
Range % 92-99    
1:4 Average % 90    
Range % 86-96    
1:8 Average % 93    
Range % 90-97    
Recovery
The recovery of human TPI1 spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.  
 
Sample Type Average % Recovery Range    
Serum (n=5) 103 99-107    
EDTA plasma (n=4) 92 85-95    
               
               
Typical Data
These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.  
 
pg/ml OD1 OD2 Average Corrected    
1800 2.377 2.433 2.405 2.308    
900 1.646 1.774 1.710 1.613    
450 1.332 1.285 1.309 1.212    
225 0.857 0.922 0.890 0.793    
112.5 0.465 0.470 0.468 0.371    
56.25 0.322 0.300 0.311 0.214    
28.1 0.203 0.204 0.204 0.107    
0 0.094 0.099 0.097      
Troubleshooting
and FAQs
Storage
Store at 2-8°C. Please refer to protocol.
Lead Time
3-5 working days after you place the order, and it takes another 3-5 days for delivery via DHL or FedEx
Description

This Human TPI1 ELISA Kit was designed for the quantitative measurement of Human TPI1 protein in serum, plasma, tissue homogenates, cell lysates. It is a Sandwich ELISA kit, its detection range is 28 pg/mL-1800 pg/mL and the sensitivity is 7 pg/mL.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
(From Uniprot)
Triosephosphate isomerase is an extremely efficient metabolic enzyme that catalyzes the interconversion between dihydroxyacetone phosphate (DHAP) and D-glyceraldehyde-3-phosphate (G3P) in glycolysis and gluconeogenesis.; It is also responsible for the non-negligible production of methylglyoxal a reactive cytotoxic side-product that modifies and can alter proteins, DNA and lipids.
Gene References into Functions
  1. Disease-associated variants change well-conserved residues in the protein's sequence and affect protein stability. PMID: 28341520
  2. A guide to the effects of a large portion of the residues of triosephosphate isomerase on catalysis, stability, druggability, and human disease has been presented. (Review) PMID: 28378917
  3. Results revealed that TPI expression might be considered as a novel prognostic factor to evaluate gastric cancer patients' survival PMID: 28489783
  4. TPI1 functions as a tumor suppressor in hepatocellular carcinoma and might serve as a potential therapeutic target for the treatment of HCC PMID: 27908734
  5. our findings are the first to identify, to our knowledge, a functional synaptic defect in TPI deficiency derived from molecular changes in the TPI dimer interface. PMID: 27031109
  6. Polyvinylpyrrolidone stabilised silver nanoparticles (60 nM; 2-6 nm diameter) selectively inhibited PfTIM with a 7-fold decrease in enzyme catalytic efficiency (K(cat)/K(m)) over hTIM. PMID: 26353595
  7. results suggest amyloid-beta oligomers induce neuronal death by triggering methylglyoxal(MG) production; increased release of MG is a direct consequence of triosephosphate isomerase nitrotyrosination due to amyloid-beta peptide action at the 2 tyrosines associated with the catalytic center PMID: 24614897
  8. TPI-PEP co-crystal structure, demonstrating that PEP directly binds into the catalytic pocket of TPI. PMID: 24598263
  9. E104D mutant is highly susceptible to proteolysis, which in all likelihood contributes to the pathogenesis of enzymopathy. In addition, the proteolysis data on wild type HsTIM illustrate an asymmetric conduct of the two monomers. PMID: 24056040
  10. Data suggest that exchange reactions during gluconeogenesis catalyzed by triose-phosphate isomerase and transaldolase do not differ between subjects with type 2 diabetes and control subjects under fasting or hyperglycemic conditions. PMID: 23736541
  11. we review the relationship between modified TPI and Alzheimer disease (AD), highlighting the relevance of this protein in AD pathology PMID: 23233058
  12. study found promoter SNPs of CKB and TPI1 were weakly associated with schizophrenia;in addition, IFNG polymorphisms were associated with schizophrenia; results suggest that IFNG and proteins affected by IFNG may play a role in the pathogenesis of schizophrenia PMID: 22623148
  13. [Review] The activity of glycolytic enzyme TPI reveals a mechanistic link between energy metabolism and age-related proteostatic dysfunction which can suppress generation of altered proteins that characterize the aged phenotype in cells and tissues. PMID: 21651995
  14. A patient with triosephosphate isomerase-deficiency was found to be homozygous for a Val231Met mutation. PMID: 21215915
  15. A proteomic approach for identification and localization of the pericellular components of chondrocytes. PMID: 21698479
  16. structural changes rather than abnormal catalysis may play an important role in the clinical manifestations of TPI deficiency; the postulated high aggregation ability of the unstable Glu104Asp mutant would lead to more serious symptoms PMID: 20546019
  17. TPI1 were up-regulated with the malignancy of prostate cancer cell lines and have their potential as serum biomarkers for indicating the developmental stage of prostate cancer. PMID: 20233700
  18. of two previously undescribed mutations: c.722 T>C (Phe240Ser) and c.28 insG; each of the two unrelated patients showed the new mutation in compound heterozygosity with the most common variant Glu104Asp, resulting in a very severe clinical pattern. PMID: 20374271
  19. the dimerization behavior of TPI is influenced by the particular mutations investigated, and by the use of a potential alternative translation initiation site in the TPI gene PMID: 17183658
  20. kinetic, thermodynamic, structural and ultrastructural data for characterization of mutant isomerase structures and for the TPI-related metabolic processes in normal and deficient cells PMID: 12023819
  21. Minor structural changes in a mutated human melanoma antigen (TPI) correspond to dramatically enhanced stimulation of a CD4+ tumor-infiltrating lymphocyte line. PMID: 12051920
  22. A patient with triosephosphate isomerase (TPI) deficiency exhibited worsening of abnormal involuntary movements of the dystonic type and developed psychiatric symptoms while on selegiline. PMID: 14743370
  23. IgG-type anti-TPI autoantibodies were detected in 24.7% of the serum samples and 24.1% of the synovial fluid samples from the patients with osteoarthritis PMID: 15146421
  24. anti-TPI antibodies are closely associated with neuropsychiatric lupus PMID: 15358119
  25. We found that a low TPI activity in the mutant cells (lower than predicted from the protein level and specific activity of the purified recombinant enzyme) is coupled with an increase in the activities of glycolytic kinases PMID: 16086671
  26. Mutations causing TPI deficiency in humans are characterized by progressive neurological dysfunction, neurodegeneration, and early death. PMID: 17008404
  27. TPI and GAPDH may be candidate Ags for an autoimmune response to neurons and axons in multiple sclerosis. PMID: 17015754
  28. anti-TPI form immune complexes in CSF and contribute to the pathogenesis of neuropsychiatric lupus by activating the complement system PMID: 17064784
  29. Triosephosphate isomerase (TPI), a glycolytic pathway enzyme, was identified as a downregulated protein in SGC7901/VCR cells PMID: 18309519
  30. TPI variants occur less frequent than expected and inactive alleles are not enriched in German centenarians PMID: 18510744
  31. human triosephosphate isomerase mutation E104D is related to alterations of a conserved water network at the dimer interface PMID: 18562316
  32. Population samples from Angola, Mozambique and S. Tome e Principe has 3 haplotypes of the TPI gene promoter variants -5A-8G-24T,-5G-8G-24T and -5G-8A-24T in malaria-infected individuals. PMID: 18792062
  33. This protein has been found differentially expressed in the Wernicke's Area from patients with schizophrenia. PMID: 19405953

Show More

Hide All

Involvement in disease
Triosephosphate isomerase deficiency (TPID)
Subcellular Location
Cytoplasm.
Protein Families
Triosephosphate isomerase family
Database Links

HGNC: 12009

OMIM: 190450

KEGG: hsa:7167

STRING: 9606.ENSP00000229270

UniGene: Hs.524219

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1